4.3 Review

Guillain-Barr, Syndrome: Modern Theories of Etiology

Journal

CURRENT ALLERGY AND ASTHMA REPORTS
Volume 11, Issue 3, Pages 197-204

Publisher

CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-011-0190-y

Keywords

Guillain-Barre syndrome; Acute inflammatory demyelinating polyradiculoneuropathy; Acute motor axonal neuropathy; Immune pathogenesis; Autoimmune disease

Funding

  1. Royal Brisbane and Women's Hospital
  2. National Health and Medical Research Council of Australia
  3. Muscular Dystrophy Association of the United States
  4. Muscular Dystrophy Association of New South Wales
  5. Bayer Schering Pharma
  6. Genzyme Corp.

Ask authors/readers for more resources

Guillain-Barr, syndrome (GBS) is a classic failure of the immune system with a life-threatening attack upon a critical self-component. The active phase of the disease is short, concordant with the latency of a primary adaptive immune response. Triggers for GBS include infection and (rarely) vaccination; cross-reactivity between infectious and neural epitopes has been well demonstrated, particularly for Campylobacter jejuni and motor axonal forms of GBS in which non-protein gangliosides are antigenic. Most people are probably exposed to a GBS trigger, but only rarely does the disease develop. We propose that GBS illustrates competing determinants of the immune system's decision about whether to mount a response, and that in unlucky affected individuals, co-presentation of cross-reactive antigens with danger signals activating pattern-recognition receptors overcomes normal self-recognition such that a primary response is initiated that attacks the nerve. Then, in most cases of GBS, the response rapidly turns off, and second attacks rarely occur. This suggests active restoration of tolerance, and specific privileged site attributes of nerve and declining danger signals as the trigger wanes may contribute to this restoration. Standard immunosuppression has not been effective in GBS. We suggest this is because immune tolerance is already being restored by the time such therapies are initiated. This in turn suggests that improvements in GBS outcomes are likely to come from better protection of the nerve cells under attack while normal resumption of tolerance is permitted to proceed rather than exploring more aggressive immunosuppressive approaches.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Response to treatment in NMOSD: the Australasian experience

Laura Clarke, Wajih Bukhari, Cullen M. O'Gorman, Elham Khalilidehkordi, Simon Arnett, Mark Woodhall, Kerri M. Prain, John D. E. Parratt, Michael H. Barnett, Mark P. Marriott, Pamela A. McCombe, Ian Sutton, Mike Boggild, Wallace Brownlee, William M. Carroll, Suzanne Hodgkinson, Richard A. L. Macdonell, Deborah F. Mason, Jennifer Pereira, Mark Slee, Chandi Das, Andrew P. D. Henderson, Allan G. Kermode, Jeannette Lechner-Scott, Patrick Waters, Jing Sun, Simon A. Broadley

Summary: This retrospective observational study evaluated the treatment response of rituximab and traditional immunosuppressive therapy in patients with AQP4 antibody positive NMOSD. The results showed that rituximab had a lower risk of first relapse and a non-significant reduction in annualized relapse rates compared to no treatment. beta-interferon and cyclophosphamide were associated with increased relapse rates. Both rituximab and traditional immunosuppressive therapy were associated with lower final EDSS compared to beta-interferon.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Psychiatry

Anti-glutamic acid decarboxylase antibody screening in first-episode psychosis

Nicola Warren, Karen Freier, Dan Siskind, Cullen O'Gorman, Stefan Blum, David Gillis, James G. Scott

Summary: Glutamic acid decarboxylase antibodies were found to be uncommon in consumers with psychosis, and there was no significant difference in prevalence compared to controls. No cases of encephalitis were identified. Targeted antibody testing guidelines should be further considered.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Article Health Care Sciences & Services

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

M. Lefort, S. Sharmin, J. B. Andersen, S. Vukusic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. De Seze, E. Maillart, H. Zephir, P. Labauge, G. Defer, C. Lebrun-Frenay, T. Moreau, E. Berger, P. Clavelou, J. Pelletier, B. Stankoff, O. Gout, E. Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Wahab, J. P. Camdessanche, A. Maurousset, H. Ben Nasr, K. Hankiewicz, C. Pottier, N. Maubeuge, C. Nifle, D. A. Laplaud, D. Horakova, D. Dimitri-Boulos, E. K. Havrdova, R. Alroughani, G. Izquierdo, S. Eichau, S. Ozakbas, F. Patti, M. Onofrj, A. Lugaresi, M. Terzi, P. Grammond, F. Grand'Maison, B. Yamout, A. Prat, M. Girard, P. Duquette, C. Boz, M. Trojano, P. McCombe, M. Slee, J. Lechner-Scott, R. Turkoglu, P. Sola, D. Ferraro, F. Granella, V Shaygannejad, J. Prevost, D. Maimone, O. Skibina, K. Buzzard, A. Van der Walt, R. Karabudak, B. Van Wijmeersch, T. Csepany, D. Spitaleri, S. Vucic, N. Koch-Henriksen, F. Sellebjerg, P. S. Soerensen, C. C. Hilt Christensen, P. Rasmussen, M. B. Jensen, J. L. Frederiksen, S. Bramow, H. K. Mathiesen, K. Schreiber, H. Butzkueven, M. Magyari, T. Kalincik, E. Leray

Summary: This study provides valuable insights into the impact of methodological decisions on the results of comparative effectiveness studies. The results suggest that there are no substantial differences in the conclusions obtained with propensity scores matching or propensity scores weighting, given that the study is sufficiently powered, models are correctly specified, and the positivity assumption is fulfilled.

BMC MEDICAL RESEARCH METHODOLOGY (2022)

Article Clinical Neurology

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

Sifat Sharmin, Francesca Bovis, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Guillermo Izquierdo, Sara Eichau, Maria Trojano, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Francois Grand'Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Murat Terzi, Oliver Gerlach, Raed Alroughani, Cavit Boz, Vahid Shaygannejad, Vincent van Pesch, Elisabetta Cartechini, Ludwig Kappos, Jeannette Lechner-Scott, Roberto Bergamaschi, Recai Turkoglu, Claudio Solaro, Gerardo Iuliano, Franco Granella, Bart Van Wijmeersch, Daniele Spitaleri, Mark Slee, Pamela McCombe, Julie Prevost, Radek Ampapa, Serkan Ozakbas, Jose Luis Sanchez-Menoyo, Aysun Soysal, Steve Vucic, Thor Petersen, Koen de Gans, Ernest Butler, Suzanne Hodgkinson, Youssef Sidhom, Riadh Gouider, Edgardo Cristiano, Tamara Castillo-Trivino, Maria Laura Saladino, Michael Barnett, Fraser Moore, Csilla Rozsa, Bassem Yamout, Olga Skibina, Anneke van der Walt, Katherine Buzzard, Orla Gray, Stella Hughes, Angel Perez Sempere, Bhim Singhal, Yara Fragoso, Cameron Shaw, Allan Kermode, Bruce Taylor, Magdolna Simo, Neil Shuey, Talal Al-Harbi, Richard Macdonell, Jose Andres Dominguez, Tunde Csepany, Carmen Adella Sirbu, Maria Pia Sormani, Helmut Butzkueven, Tomas Kalincik

Summary: This study identifies the clinicodemographic characteristics of 6-month confirmed disability progression events in multiple sclerosis (MS) patients, which can help identify those at high risk of sustained long-term disability. This knowledge will improve the assessment of therapy effects on long-term disability accrual in future trials.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Review Clinical Neurology

The role of sex and pregnancy in multiple sclerosis: what do we know and what should we do?

Pamela A. McCombe

Summary: This review summarizes the data on sex differences and pregnancy in multiple sclerosis (MS), and discusses the possible mechanisms behind these effects. Practical suggestions for addressing these issues are also provided.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2022)

Article Clinical Neurology

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study

Marianna Vitkova, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Vahid Shaygannejad, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Catherine Larochelle, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Pierre Grammond, Helmut Butzkueven, Katherine Buzzard, Olga Skibina, Bassem Yamout, Rana Karabudak, Oliver Gerlach, Jeannette Lechner-Scott, Davide Maimone, Roberto Bergamaschi, Vincent Van Pesch, Gerardo Iuliano, Elisabetta Cartechini, Maria Jose Sa, Radek Ampapa, Michael Barnett, Stella E. Hughes, Cristina M. Ramo-Tello, Suzanne Hodgkinson, Daniele L. A. Spitaleri, Thor Petersen, Ernest Gerard Butler, Mark Slee, Chris McGuigan, Pamela Ann McCombe, Franco Granella, Edgardo Cristiano, Julie Prevost, Bruce Taylor, Josaa Luis Sanchez-Menoyo, Guy Laureys, Liesbeth Van Hijfte, Steve Vucic, Richard A. Macdonell, Orla Gray, Javier Olascoaga, Norma Deri, Yara Dadalti Fragoso, Cameron Shaw, Tomas Kalincik

Summary: This study investigated the association between latitude of residence, UVB exposure, and the severity of multiple sclerosis (MS). The findings revealed that in temperate zones, latitude is associated with the severity of MS, and this association is mainly driven by UVB exposure.

NEUROLOGY (2022)

Article Neurosciences

Cloning of a new form of EAAT2/GLT-1 from human and rodent brains

A. Lee, S. Klinkradt, P. A. McCombe, D. Pow

Summary: In this study, a novel splice variant of glutamate transporter 1, named GLT-1d/EAAT2d, was cloned from human and rodent brains. The splice variant was found to be abundantly expressed in the brain, spinal cord, retina, liver, and testis, and functions as a glutamate transporter. These findings suggest that it may play a functional role in glutamate homeostasis in the nervous system of rodents and humans.

NEUROSCIENCE LETTERS (2022)

Review Clinical Neurology

HLA and amyotrophic lateral sclerosis: a systematic review and meta-analysis

R. J. Nona, J. M. Greer, R. D. Henderson, P. A. McCombe

Summary: This systematic review and meta-analysis examines the association between HLA and ALS. The study finds three alleles of interest, but does not confirm all previously reported associations. The study also identifies methodological limitations and calls for further modern research to validate the results.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Novel Variants of ANO5 in Two Patients With Limb Girdle Muscular Dystrophy: Case Report

Matthew Katz, Fleur C. Garton, Mark Davis, Robert D. Henderson, Pamela A. McCombe

Summary: This study reports on two unrelated patients with Limb girdle muscular dystrophy who were found to have novel variants in ANO5. The findings expand the genotypic spectrum of ANO5 disease and support the utility of next generation sequencing in the diagnosis of patients with Limb girdle muscular dystrophy phenotype.

FRONTIERS IN NEUROLOGY (2022)

Article Dentistry, Oral Surgery & Medicine

Oral health-related quality of life is more strongly correlated with mental health than with oral health in relapsing-remitting multiple sclerosis

Matthew R. Nangle, Nithin Manchery, Andrew Swayne, Helen Boocock, Stefan Blum, Julie D. Henry

Summary: This study aims to test whether individuals with relapsing-remitting MS have poorer oral health-related quality of life (OHRQoL) than demographically matched controls, and to determine the variables associated with worse OHRQoL.

JOURNAL OF ORAL REHABILITATION (2023)

Article Clinical Neurology

Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitis

James Broadley, Robb Wesselingh, Paul Beech, Udaya Seneviratne, Chris Kyndt, Katherine Buzzard, Cassie Nesbitt, Wendyl D'Souza, Amy Brodtmann, Richard Macdonell, Tomas Kalincik, Terence J. O'Brien, Helmut Butzkueven, Mastura Monif

Summary: The utility of neuroimaging characteristics as biomarkers of prognosis in seropositive autoimmune encephalitis (AE) was examined in this study. MRI and PET imaging were assessed, and abnormalities were found in 35.1% and 46.4% of patients, respectively. Initial whole brain and hippocampal volumes were below the 5th and 20th percentile compared to a healthy database. After a median follow-up of 715 days, 85.2% had good functional outcome. Structural and inflammatory changes of the MTL were associated with prognosis in seropositive AE.

NEUROLOGICAL SCIENCES (2023)

Article Clinical Neurology

Phenotypic variability within the desminopathies: A case series of three patients

Dennis Yeow, Matthew Katz, Robert Henderson, Sandhir Prasad, Russell Denman, Stefan Blum, Mark Davis, Thomas Robertson, Pamela McCombe

Summary: The DES gene encodes desmin, an important protein in skeletal, cardiac, and smooth muscle. Mutations in the DES gene can lead to a range of muscular disorders known as desminopathies. We present three cases of desminopathy that demonstrate the phenotypic diversity of this disorder, and discuss factors that contribute to clinical differences between patients with different desmin variants and within families.

FRONTIERS IN NEUROLOGY (2023)

Letter Clinical Neurology

Very late-onset limb-girdle congenital myasthenic syndrome due to GFPT1 mutation

Shadi El-Wahsh, Rajiv Wijesinghe, Jessica Qiu, Rob Heard, Marion Stoll, Stephen Reddel

MUSCLE & NERVE (2023)

Meeting Abstract Clinical Neurology

Novel real world evidence from mSGo, a digital support program for secondary Progressive multiple sclerosis patients in Australia using siponimod

T. Hardy, P. Aouad, M. Barnett, S. Blum, S. Broadley, W. Carroll, D. Crimmins, D. Griffiths, S. Hodgkinson, J. Lechner-Scott, A. Lee, R. Malhotra, P. McCombe, J. Parratt, C. Plummer, A. van der Walt, K. Martel, R. Walker

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data

Todd A. Hardy, John Parratt, Heidi Beadnall, Stefan Blum, Richard Macdonell, Roy G. Beran, Neil Shuey, Andrew Lee, William Carroll, Cameron Shaw, Richard Worrell, Jana Moody, Mamdouh Sedhom, Michael Barnett, Steve Vucic

Summary: In this study of Australian patients with RRMS initiated on teriflunomide, high treatment satisfaction and adherence were reported at 24 and 48 weeks. Patient-reported disability remained low, with improvements in work capacity and daily life activity observed, while most patients remained relapse-free.

BMJ NEUROLOGY OPEN (2022)

No Data Available